• placebo
  • Depending on the treatment Panel, patients will be assigned to intranasal placebo or intranasal esketamine 14 mg, 28 mg, 56 mg, or 84 mg. (clinicaltrials.gov)
  • After appropriate screening to determine eligibility, 64 subjects with treatment resistant depression will be randomized to receive three infusions of either infliximab (Remicade®) or placebo (salt water) in the Emory Infliximab Infusion Center in the Division of Digestive Diseases, Emory University School of Medicine. (clinicaltrials.gov)
  • Spravato
  • In the company statement, Janssen said it would work quickly to educate and certify treatment centers, so health care providers could start offering Spravato. (usatoday.com)